Analysts Set Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) PT at $48.50

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average rating of “Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $48.50.

Several brokerages have recently issued reports on AAPG. Oppenheimer assumed coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective for the company. Piper Sandler began coverage on shares of Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. BTIG Research started coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a report on Monday, November 24th.

Institutional Trading of Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at $204,000. Chevy Chase Trust Holdings LLC purchased a new stake in Ascentage Pharma Group International during the second quarter worth $227,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter valued at $383,000. Finally, Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the second quarter valued at $391,000.

Ascentage Pharma Group International Stock Performance

Shares of AAPG stock opened at $27.88 on Friday. The business has a fifty day moving average of $31.96 and a 200 day moving average of $36.75. Ascentage Pharma Group International has a 1 year low of $16.50 and a 1 year high of $48.45. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.